As of June 7, 2025, Heat Biologics Inc (HTBX) reports a ROE (Return on Equity) of -31.01%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Heat Biologics Inc's ROE (Return on Equity)
Over recent years, Heat Biologics Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2021-12-31 | -31.01% |
| 2020-12-31 | -22.42% |
| 2019-12-31 | -147.21% |
| 2018-12-31 | -51.91% |
| 2017-12-31 | -160.00% |
This slight downward trend highlights how Heat Biologics Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Heat Biologics Inc's ROE (Return on Equity) to Peers
To better understand Heat Biologics Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Heat Biologics Inc (HTBX) | -31.01% |
| Oragenics Inc (OGEN) | 4987.46% |
| GT Biopharma Inc (GTBP) | 788.14% |
| ContraFect Corp (CFRX) | 549.79% |
| CTI Biopharma Corp (CTIC) | 529.05% |
| Abbvie Inc (ABBV) | 128.66% |
Compared to its competitors, Heat Biologics Inc's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.